



Helsingborg October 30, 2023

Press release

The Nomination Committee has been appointed for the Aqilion Annual General Meeting 2025

Aqilion AB (publ) hereby announces that the Nomination Committee for the 2025 Annual General Meeting has been appointed and consists of:

- Hites Jina, appointed by the shareholder LMK Forward AB
- Linus Wiebe, appointed by the shareholder Fåhraeus Start Up and Growth AB
- Katarina Berggren, appointed by the shareholder Aktiebolaget Grenspecialisten
- Philip Jansson, appointed by the shareholder Länsförsäkringar Göteborg och Bohuslän

The Nomination Committee has been appointed in accordance with guidelines established at the 2024 Annual General Meeting. As of September 30, 2024, the Nomination Committee together represents 52.1 percent of the shares in Aqilion. In accordance with the instructions, members of the Nomination Committee will appoint the Chairman among themselves.

The Nomination Committee primarily responsible for preparing and presenting proposals for the 2025 Annual General Meeting regarding the Chairman of the meeting, election of Board members and Chairman of the Board, the fees to be paid to the Board Chairman and the Board members, remuneration to the auditor and election of the auditor. Finally, the Nomination Committee will propose principles for the appointment of the Nomination Committee (if the Nomination Committee considers that the current principles and instructions should be updated).

The Annual General Meeting of AQILION AB (publ) is planned to be held on June 3, 2025, at the Company office in Helsingborg, Sweden.

Shareholders who wish to submit proposals and views to the Nomination Committee of Aqilion AB, to: Valberedning, AQILION AB, c/o HETCH AB, Redaregatan 48, 252 36 Helsingborg, or via e-mail to info@aqilion.com. To ensure that proposals can be processed by the Nomination committee, these must be received in good time before the General Meeting, but no later than January 31, 2025.

The Nomination Committee's proposal will be presented in the notice to the Annual General Meeting and on the Aqilion website.

For further information, please contact:

Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases.

We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The innovation approach is based on solid scientific grounds, in disease areas where we, with reasonable assumptions, can understand the underlying biology, clinical relevance of the mechanism, potential patient benefit and the likelihood for finding a partner.

The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion executes its development programs in a partly virtual organization in close collaboration with selected partners, with specific expertise in drug development.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com